Recruiting clinical trials
Hematologic malignancies
Multiple myeloma
B-cell malignancies
Myeloid malignancies
Classical hematology
Solid tumors
Lung cancer
Bladder cancer
Head and neck cancer
Prostate cancer
Colorectal cancer
Advanced solid tumors
Video explorer Digital resources
Enter a search term to see results

Disease area

Hematologic malignancies
Multiple myeloma B-cell malignancies Myeloid malignancies Classical hematology
Solid tumors
Lung cancer Bladder cancer Head and neck cancer Prostate cancer Colorectal cancer Advanced solid tumors
Showing 2 recruiting clinical trials
IR-NMIBC with susceptible FGFR gene alterations
MoonRISe-1
Phase
NCT06319820
Compound
Erda-iDRS
View trial design
BCG-treated HR-NMIBC with susceptible FGFR gene alterations
MoonRISe-3
Phase
NCT06919965
Compound
Erda-iDRS
View trial design

The safety and efficacy of the investigational use of these products have not been determined.

There is no guarantee that the investigational uses listed will be filed with and/or approved for marketing by any regulatory agency.

BCG, Bacillus Calmette-Guérin; erda-iDRS, erdafitinib intravesical drug releasing system; FGFR, fibroblast growth factor receptor; HR, high-risk; IR, intermediate-risk; NMIBC, non-muscle-invasive bladder cancer.

Your use of information on this site is subject to the terms of our Legal Notice. Please see our Privacy Statement. This site is published by Johnson & Johnson Services, Inc., which is solely responsible for its contents. Capitalized product names are trademarks of Johnson & Johnson or its affiliated companies. This information is intended for a global audience. Information specific to individual countries is identified where it appears. All third-party trademarks used herein are registered trademarks of their respective owners. Last updated: 02/26/2026.
© Johnson & Johnson and its affiliates 2026 05/26 cp-564163v2